Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Voyager Therapeutics (VYGR) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Voyager Therapeutics' Change in Receivables fell 8939.1% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.8 million, marking a year-over-year increase of 6742.52%. This contributed to the annual value of -$78.6 million for FY2024, which is 19812.35% down from last year.
  • Voyager Therapeutics' Change in Receivables amounted to $1.5 million in Q3 2025, which was down 8939.1% from $51000.0 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Change in Receivables ranged from a high of $25.0 million in Q1 2023 and a low of -$79.3 million during Q1 2024
  • For the 3-year period, Voyager Therapeutics' Change in Receivables averaged around -$6.5 million, with its median value being $492000.0 (2024).
  • Per our database at Business Quant, Voyager Therapeutics' Change in Receivables crashed by 41725.2% in 2024 and then surged by 10015.0% in 2025.
  • Quarter analysis of 3 years shows Voyager Therapeutics' Change in Receivables stood at $25.0 million in 2023, then plummeted by 157.8% to -$14.4 million in 2024, then skyrocketed by 110.46% to $1.5 million in 2025.
  • Its Change in Receivables stands at $1.5 million for Q3 2025, versus $51000.0 for Q2 2025 and $119000.0 for Q1 2025.